Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL.
[Journal of Clinical Oncology]
6445212 XQWZWZRX items 1 apa default asc 1
Metzger, M. L., Link, M. P., Billett, A. L., Flerlage, J., Lucas, J. T., Mandrell, B. N., Ehrhardt, M. J., Bhakta, N., Yock, T. I., Friedmann, A. M., de Alarcon, P., Luna-Fineman, S., Larsen, E., Kaste, S. C., Shulkin, B., Lu, Z., Li, C., Hiniker, S. M., Donaldson, S. S., … Krasin, M. J. (2021). Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. Journal of Clinical Oncology, JCO.20.03286. https://doi.org/10.1200/JCO.20.03286 Cite
Scientists discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
[Blood Cancer Journal]
Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates.
[Blood Cancer Journal]
Scientists demonstrated that Bcl3 impacted pancreatic carcinogenesis by restraining cancer stem cell expansion and by curtailing an aggressive and metastatic tumor burden in pancreatic ductal adenocarcinoma across species.
6606345 4YS6S5AQ items 1 apa default asc 1
Ai, J., Wörmann, S. M., Görgülü, K., Vallespinos, M., Zagorac, S., Alcala, S., Wu, N., Kabacaoglu, D., Berninger, A., Navarro, D., Kaya-Aksoy, E., Ruess, D. A., Ciecielski, K. J., Kowalska, M., Demir, E. I., Ceyhan, G. O., Heid, I., Braren, R., Riemann, M., … Algül, H. (2021). BCL3 couples cancer stem cell enrichment with pancreatic cancer molecular subtypes. Gastroenterology, 0(0). https://doi.org/10.1053/j.gastro.2021.03.051 Cite
Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Tecentriq® as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
1254621 nan items 1 apa default asc 1
Researchers report an essential cross-talk between CAR T cell subsets and the TME for tumor control in an immunocompetent mouse B cell lymphoma model of anti-CD19 CAR T cell therapy.
6445218 736KL2EX items 1 apa default asc 1
Boulch, M., Cazaux, M., Loe-Mie, Y., Thibaut, R., Corre, B., Lemaître, F., Grandjean, C. L., Garcia, Z., & Bousso, P. (2021). A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Science Immunology, 6(57). https://doi.org/10.1126/sciimmunol.abd4344 Cite
ox-LDL inhibited circRSF1 and histone deacetylase 1 (HDAC1) expression while upregulated miR-135b-5p expression in HUVECs.
6445212 9PU5W685 items 1 apa default asc 1
Zhang, X., Lu, J., Zhang, Q., Luo, Q., & Liu, B. (2021). CircRNA RSF1 regulated ox-LDL induced vascular endothelial cells proliferation, apoptosis and inflammation through modulating miR-135b-5p/HDAC1 axis in atherosclerosis. Biological Research, 54(1), 11. https://doi.org/10.1186/s40659-021-00335-5 Cite
Scientists showed that adult T cell leukemia/lymphoma (ATL) could be detected early in HTLV-1-carriers through quantification of T-cell receptor (TCR)Vβ subunit diversity on T-cells infected with HTLV-1 using an ‘oligoclonality index’.
[Blood Cancer Journal]
6445218 TY5E796M items 1 apa default asc 1
Wolf, S. N., Haddow, J., Greiller, C., Taylor, G. P., Cook, L. B. M., & Rowan, A. G. (2021). Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early. Blood Cancer Journal, 11(3), 1–11. https://doi.org/10.1038/s41408-021-00458-8 Cite
In this research, a novel lncRNA was identified overexpressed in the main subtypes of peripheral T cell lymphoma, and designated as T cell lymphoma-associated lncRNA1.
[Cell Death & Disease]
6445218 5S9ZLEV6 items 1 apa default asc 1
Zhao, P., Ji, M.-M., Fang, Y., Li, X., Yi, H.-M., Yan, Z.-X., Cheng, S., Xu, P.-P., Janin, A., Wang, C.-F., Wang, L., & Zhao, W.-L. (2021). A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes. Cell Death & Disease, 12(4), 1–14. https://doi.org/10.1038/s41419-021-03594-y Cite
Researchers engineered trispecific duoCAR-T cells with lentiviral vectors encoding two CAR open reading frames that target CD19, CD20, and CD22.
[Science Translational Medicine]
6445218 5TCT9CEV items 1 apa default asc 1
Schneider, D., Xiong, Y., Wu, D., Hu, P., Alabanza, L., Steimle, B., Mahmud, H., Anthony-Gonda, K., Krueger, W., Zhu, Z., Dimitrov, D. S., Orentas, R. J., & Dropulić, B. (2021). Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Science Translational Medicine, 13(586). https://doi.org/10.1126/scitranslmed.abc6401 Cite
To understand the metabolic state of rare, early-activated T cells, scientists adapted mass cytometry to quantify metabolic regulators at single-cell resolution in parallel with cell signaling, proliferation, and effector function.
6445218 8IATMNRC items 1 apa default asc 1
Levine, L. S., Hiam-Galvez, K. J., Marquez, D. M., Tenvooren, I., Madden, M. Z., Contreras, D. C., Dahunsi, D. O., Irish, J. M., Oluwole, O. O., Rathmell, J. C., & Spitzer, M. H. (2021). Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response. Immunity, 0(0). https://doi.org/10.1016/j.immuni.2021.02.018 Cite